Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tepoxalin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 4/20 | 1.00 |
| ▸ | ALOX5 known ✓ | P09917 | 2/20 | 1.00 |
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 0.54 |
| ▸ | RXRA | P19793 | 2/20 | 0.66 |
| ▸ | RXRB | P28702 | 2/20 | 0.66 |
| ▸ | RXRG | P48443 | 2/20 | 0.66 |
| ▸ | CCKAR | P32238 | 10/20 | 0.64 |
| ▸ | MALT1 | Q9UDY8 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | THPO | P40225 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tepoxalin SCHEMBL9519652 | 0.99 | PTGS2 (0.98) | PTGS2ALOX5RXRARXRBRXRG | |
| Tepoxalin SCHEMBL28256087 | 0.93 | ALOX5 (0.87) | PTGS2ALOX5RXRARXRBRXRG | |
| SCHEMBL9519214 | 0.91 | ALOX5 (0.83) | PTGS2ALOX5RXRARXRBRXRG | |
| SCHEMBL9522599 | 0.91 | ALOX5 (0.83) | PTGS2ALOX5RXRARXRBRXRG | |
| SCHEMBL9520508 | 0.91 | ALOX5 (0.83) | PTGS2ALOX5RXRARXRBRXRG | |
| SCHEMBL9519177 | 0.90 | ALOX5 (0.82) | PTGS2ALOX5RXRARXRBRXRG | |
| SCHEMBL9697622 | 0.90 | PTGS2 (0.82) | PTGS2ALOX5RXRARXRBRXRG | |
| SCHEMBL9519478 | 0.90 | PTGS2 (0.81) | PTGS2ALOX5RXRARXRBRXRG | |
| SCHEMBL9519062 | 0.90 | PTGS2 (0.81) | PTGS2ALOX5RXRARXRBRXRG | |
| SCHEMBL9080028 | 0.89 | PTGS2 (0.81) | PTGS2ALOX5RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4805 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000741-A1 | METHOD OF AMELIORATING A PRO-INFLAMMATORY IMMUNOPHENOTYPE IN FARBER DISEASE SUBJECTS BY REPEATED ADMINISTRATION OF A RECOMBINANT HUMAN ACID CERAMIDASE | ACERAGEN INC (US) | 2026-01-01 | — | — | US | claimed |
| EP-3877056-B1 | TEPOXALIN TARGETING OF ABCB1 OVEREXPRESSING CANCERS | BROAD INST INC (US) | 2025-07-02 | — | — | EP | claimed |
| US-12313632-B2 | Tepoxalin targeting of ABCB1 overexpressing cancers | THE BROAD INSTITUTE, INC. (US) | 2025-05-27 | — | — | US | claimed |
| CN-119732950-A | Application of composition of Tepoxalin and taxanes in treating solid tumor | 典晶医药(无锡)有限公司 | 2025-04-01 | — | — | CN | claimed |
| US-20250099590-A1 | HIGH DENSITY ULTRASOUND COUPLING GEL AND METHODS OF USE THEREOF | ZETROZ SYSTEMS LLC (US) | 2025-03-27 | — | — | US | claimed |
| EP-4507694-A1 | SOFT CHEWABLE VETERINARY DOSAGE FORM | KRKA, d.d., Novo mesto (SI) | 2025-02-19 | — | — | EP | claimed |
| US-20250041208-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2025-02-06 | — | — | US | claimed |
| EP-4444277-A1 | NEW INJECTABLE COMBINATION FORMULATION | Nanexa AB (SE) | 2024-10-16 | — | — | EP | claimed |
| CN-118647367-A | Novel injectable combination formulations | 南爱克萨股份公司 | 2024-09-13 | — | — | CN | claimed |
| US-20240288444-A1 | BIOMARKERS PREDICTIVE OF CYTOKINE RELEASE SYNDROME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2024-08-29 | — | — | US | claimed |
| WO-1996030393-A1 | A METHOD FOR THE SYNTHESIS OF MIXTURES OF COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1996-10-03 | — | — | WO | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| EP-0663856-A1 | APPARATUS AND METHOD FOR MULTIPLE SIMULTANEOUS SYNTHESIS | WARNER-LAMBERT COMPANY (US) | 1995-07-26 | — | — | EP | claimed |
| WO-1994008711-A1 | APPARATUS AND METHOD FOR MULTIPLE SIMULTANEOUS SYNTHESIS | WARNER-LAMBERT COMPANY (US) | 1994-04-28 | — | — | WO | claimed |
| EP-0248594-B1 | Pharmacologically active 1,5-diaryl-3-substituted-pyrazoles and method for synthesizing the same | ORTHO PHARMA CORP (US) | 1993-11-24 | — | — | EP | claimed |
| US-5164381-A | Cardiovascular, antiinflammatory | ORTHO PHARMACEUTICAL CORPORATION (US) | 1992-11-17 | — | — | US | claimed |
| EP-0480690-A1 | Aqueous ophthalmic microemulsions of tepoxalin | CIBA-GEIGY AG (CH) | 1992-04-15 | — | — | EP | claimed |
| US-4898952-A | Regioselective synthesis of a 1,5-disubstituted pyrazole | ORTHO PHARMACEUTICAL CORPORATION (US) | 1990-02-06 | — | — | US | claimed |
| US-4826868-A | 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-05-02 | — | — | US | claimed |
| EP-0248594-A2 | Pharmacologically active 1,5-diaryl-3-substituted-pyrazoles and method for synthesizing the same | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-12-09 | — | — | EP | claimed |